| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 5,442 | 14,189 | 5,874 | 13,469 |
| Research and development | 8,597 | 10,672 | 13,606 | 26,864 |
| General and administrative | 4,174 | 5,878 | 6,824 | 5,198 |
| Impairment charges | 587 | - | - | - |
| Restructuring | 0 | 83 | 175 | - |
| Total operating expenses | 13,358 | 16,633 | 20,605 | 32,062 |
| Loss from operations | -7,916 | -2,444 | -14,731 | -18,593 |
| Interest income | 532 | 740 | - | 1,182 |
| Other income (expense), net | 2 | 4 | - | -26 |
| Total other income, net | 534 | 744 | - | 1,156 |
| Net loss before income taxes | -7,382 | - | - | -17,437 |
| Income tax benefit | 0 | - | - | -290 |
| Net loss and comprehensive loss | -7,382 | -1,700 | - | -17,147 |
| Earnings per share, basic | -0.13 | -0.03 | -0.25 | -0.32 |
| Earnings per share, diluted | -0.13 | -0.03 | -0.25 | -0.32 |
| Weighted average number of shares outstanding, basic | 56,280,844 | 56,026,767 | 55,376,188 | 54,124,862 |
| Weighted average number of shares outstanding, diluted | 56,280,844 | 56,026,767 | 55,376,188 | 54,124,862 |
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)